Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

faes farma s.a. - mesalazin - suppositorier - 1 g

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

faes farma s.a. - mesalazin - suppositorier - 500 mg

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - entacapon - filmovertrukne tabletter - 200 mg

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - entacapon - filmovertrukne tabletter - 200 mg

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

nordic prime aps - lornoxicam - pulver og solvens til injektionsvæske, opløsning - 8 mg

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

seqirus s.r.l.  - influenzavirusoverfladeantigener (hæmagglutinin og neuraminidase) af stamme: a / tyrkiet / tyrkiet / 1/05 (h5n1) -lignende stamme (nibrg-23) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mod h5n1-subtype af influenza-a-virus. denne angivelse er baseret på immunogenicitet data fra raske forsøgspersoner i alderen fra 18 år og op efter administration af to doser af vaccinen, der indeholder a/tyrkiet/tyrkiet/1/05 (h5n1)-lignende stamme. aflunov bør anvendes i overensstemmelse med officielle anbefalinger.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa - hemophilia a - koagulationsfaktor viii - behandling og profylakse af blødning hos patienter med hæmofili a (medfødt faktor viii-mangel). novoeight kan bruges til alle aldersgrupper.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmathen s.a. - quetiapin fumarat - depottabletter - 150 mg

Δανία - Δανικά - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmathen s.a. - quetiapin fumarat - depottabletter - 200 mg